Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  22 results for ""Glucagon-Like Peptides""

Your Filters

Content Provider : Vocational and Career Collection
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function.

Subjects: KIDNEY failure; PATIENT safety; RESEARCH funding

  • Source: Journal of Clinical Pharmacology. Jun2024, Vol. 64 Issue 6, p744-754. 11p.

Record details

Read More Add to Saved list
×
Academic Journal

Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide.

Subjects: VOMITING prevention; GLYCOSYLATED hemoglobin; NAUSEA

  • Source: Journal of Clinical Pharmacology. Feb2024, Vol. 64 Issue 2, p215-226. 12p.

Record details

Read More Add to Saved list
×
Academic Journal

New and Potential Treatments To Lengthen Life in Pediatric Short Bowel Syndrome.

Subjects: GHRELIN; GLUCAGON-like peptides; PHYSIOLOGICAL adaptation

  • Source: Pediatric Nursing. Jan/Feb2019, Vol. 45 Issue 1, p23-30. 8p. 3 Charts.

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Appetite-Regulating Hormones in Human Milk: A Plausible Biological Factor for Obesity Risk Reduction?

Subjects: PREVENTION of obesity; MOTHERS; STATISTICS

  • Source: Journal of Human Lactation. Aug2021, Vol. 37 Issue 3, p603-614. 12p.

Record details

Read More Add to Saved list
×
Academic Journal

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

Subjects: NOVO Nordisk A/S; REGULATION of body weight; PHARMACOKINETICS

  • Source: Lancet. 5/8/2021, Vol. 397 Issue 10286, p1736-1748. 13p.

Record details

Read More Add to Saved list
×
Academic Journal

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Subjects: TYPE 2 diabetes; WEIGHT loss; OBESITY

  • Source: Lancet. 3/13/2021, Vol. 397 Issue 10278, p971-984. 14p.

Record details

Read More Add to Saved list
×
Academic Journal

Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.

Subjects: DRUG interactions; TYPE 2 diabetes; ORAL drug administration

  • Source: Nursing for Women's Health. Oct2020, Vol. 24 Issue 5, p370-376. 7p.

Record details

Read More Add to Saved list
×
Academic Journal

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Subjects: TYPE 2 diabetes; GLOMERULAR filtration rate; GLUCAGON-like peptide-1 agonists

  • Source: Lancet. Jul2019, Vol. 394 Issue 10193, p131-138. 8p.

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Subjects: GLUCAGON-like peptide-1 receptor; GLUCAGON-like peptide 1; TYPE 2 diabetes treatment

  • Source: Lancet. 11/17/2018, Vol. 392 Issue 10160, p2180-2193. 14p.

Record details

Read More Add to Saved list
×
Academic Journal

Is it time to REWIND the cardiorenal clock in diabetes?

Subjects: TYPE 2 diabetes; DIABETES; IMMUNOGLOBULINS

  • Source: Lancet. Jul2019, Vol. 394 Issue 10193, p95-97. 3p.

Record details

Read More Add to Saved list
×
  • 1-10 of  22 results for ""Glucagon-Like Peptides""